TLDR Affirm posted Q2 EPS of $0.37, beating the $0.28 estimate by $0.09, while revenue hit $1.12 billion versus $1.06 billion expected. Stock fell 4.4% to $59.42TLDR Affirm posted Q2 EPS of $0.37, beating the $0.28 estimate by $0.09, while revenue hit $1.12 billion versus $1.06 billion expected. Stock fell 4.4% to $59.42

Affirm (AFRM) Stock: Why Shares Dropped Despite Beating Earnings

2026/02/06 21:16
3 min read

TLDR

  • Affirm posted Q2 EPS of $0.37, beating the $0.28 estimate by $0.09, while revenue hit $1.12 billion versus $1.06 billion expected.
  • Stock fell 4.4% to $59.42 as management left out forward EPS guidance and gave mixed Q3 revenue projections.
  • CEO Max Levchin sold 666,666 shares for $53.7 million at $80.62 in January, weeks before the earnings report.
  • The stock trades at a P/E ratio of 88.69 and sits below its 50-day and 200-day moving averages.
  • Analysts keep a Moderate Buy rating with a $89.16 average price target following recent upgrades from Morgan Stanley and Needham.

Affirm delivered a strong earnings beat Thursday but shares still tumbled. The buy now, pay later company reported Q2 earnings of $0.37 per share, crushing the $0.28 consensus by $0.09.

Revenue reached $1.12 billion for the quarter. That topped Wall Street’s $1.06 billion estimate. Both metrics came in ahead of expectations.

Yet the stock closed down 4.4% at $59.42. Volume exploded to 12.9 million shares, double the typical 6.1 million daily average. Something in the report spooked investors.


AFRM Stock Card
Affirm Holdings, Inc., AFRM

The culprit was forward guidance. Management projected Q3 revenue of $970 million to $1 billion, slightly under the $978.3 million consensus. Full-year revenue guidance of $4.09 billion to $4.15 billion matched estimates.

The Missing Piece That Hurt Sentiment

The real problem was what Affirm didn’t provide. The company left forward EPS guidance completely blank in its update. No projections for future earnings per share at all.

That gap created instant uncertainty. Investors had no roadmap for profitability despite the current quarter’s strong performance. Markets punish uncertainty.

Technical factors didn’t help matters. The stock trades below its 50-day moving average of $72.00 and 200-day average of $74.34. At a P/E ratio of 88.69, valuations are stretched.

High-multiple stocks often see profit-taking after earnings. Even good results can trigger selling when the stock already prices in aggressive growth.

Affirm’s revenue growth came from higher gross merchandise volume. That signals healthy demand for its core services. The company posted a net margin of 6.74% and return on equity of 7.75%.

Insider Sales Before the Drop

CEO Max Levchin made a massive sale in early January. He sold 666,666 shares at $80.62 each for approximately $53.7 million. That was weeks before this earnings report when shares traded higher.

CFO Robert O’Hare also sold 36,401 shares at $80.00 for $2.9 million. His sale cut his position by 96.38%. Over three months, insiders unloaded about 711,256 shares worth $57.2 million total.

The timing raised eyebrows. Large insider sales ahead of a stock decline always draw attention. Insiders may have legitimate reasons for selling, but the optics aren’t great.

Wall Street analysts remained mostly positive. Morgan Stanley upgraded to Overweight. Needham jumped from Hold to Buy with a $100 target. Cantor Fitzgerald assigned a Strong Buy rating.

The consensus sits at Moderate Buy with an $89.16 average price target. That implies 50% upside from current levels. Three analysts rate it Strong Buy, nineteen say Buy, and eight call it a Hold.

Institutional investors control 69.29% of shares. The company carries a debt-to-equity ratio of 2.40 with quick and current ratios of 12.80. Market cap stands at $19.61 billion.

Over the past year, shares traded between $30.90 and $100.00. The stock is down 19.29% over three months and off 3.77% over the past year. Volume on earnings day showed investors weren’t willing to hold through the uncertainty.

The post Affirm (AFRM) Stock: Why Shares Dropped Despite Beating Earnings appeared first on Blockonomi.

Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.0005407
$0.0005407$0.0005407
+4.36%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Cashing In On University Patents Means Giving Up On Our Innovation Future

Cashing In On University Patents Means Giving Up On Our Innovation Future

The post Cashing In On University Patents Means Giving Up On Our Innovation Future appeared on BitcoinEthereumNews.com. “It’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress,” writes Pipes. Getty Images Washington is addicted to taxing success. Now, Commerce Secretary Howard Lutnick is floating a plan to skim half the patent earnings from inventions developed at universities with federal funding. It’s being sold as a way to shore up programs like Social Security. In reality, it’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress. Yes, taxpayer dollars support early-stage research. But the real payoff comes later—in the jobs created, cures discovered, and industries launched when universities and private industry turn those discoveries into real products. By comparison, the sums at stake in patent licensing are trivial. Universities collectively earn only about $3.6 billion annually in patent income—less than the federal government spends on Social Security in a single day. Even confiscating half would barely register against a $6 trillion federal budget. And yet the damage from such a policy would be anything but trivial. The true return on taxpayer investment isn’t in licensing checks sent to Washington, but in the downstream economic activity that federally supported research unleashes. Thanks to the bipartisan Bayh-Dole Act of 1980, universities and private industry have powerful incentives to translate early-stage discoveries into real-world products. Before Bayh-Dole, the government hoarded patents from federally funded research, and fewer than 5% were ever licensed. Once universities could own and license their own inventions, innovation exploded. The result has been one of the best returns on investment in government history. Since 1996, university research has added nearly $2 trillion to U.S. industrial output, supported 6.5 million jobs, and launched more than 19,000 startups. Those companies pay…
Share
BitcoinEthereumNews2025/09/18 03:26
China Blocks Nvidia’s RTX Pro 6000D as Local Chips Rise

China Blocks Nvidia’s RTX Pro 6000D as Local Chips Rise

The post China Blocks Nvidia’s RTX Pro 6000D as Local Chips Rise appeared on BitcoinEthereumNews.com. China Blocks Nvidia’s RTX Pro 6000D as Local Chips Rise China’s internet regulator has ordered the country’s biggest technology firms, including Alibaba and ByteDance, to stop purchasing Nvidia’s RTX Pro 6000D GPUs. According to the Financial Times, the move shuts down the last major channel for mass supplies of American chips to the Chinese market. Why Beijing Halted Nvidia Purchases Chinese companies had planned to buy tens of thousands of RTX Pro 6000D accelerators and had already begun testing them in servers. But regulators intervened, halting the purchases and signaling stricter controls than earlier measures placed on Nvidia’s H20 chip. Image: Nvidia An audit compared Huawei and Cambricon processors, along with chips developed by Alibaba and Baidu, against Nvidia’s export-approved products. Regulators concluded that Chinese chips had reached performance levels comparable to the restricted U.S. models. This assessment pushed authorities to advise firms to rely more heavily on domestic processors, further tightening Nvidia’s already limited position in China. China’s Drive Toward Tech Independence The decision highlights Beijing’s focus on import substitution — developing self-sufficient chip production to reduce reliance on U.S. supplies. “The signal is now clear: all attention is focused on building a domestic ecosystem,” said a representative of a leading Chinese tech company. Nvidia had unveiled the RTX Pro 6000D in July 2025 during CEO Jensen Huang’s visit to Beijing, in an attempt to keep a foothold in China after Washington restricted exports of its most advanced chips. But momentum is shifting. Industry sources told the Financial Times that Chinese manufacturers plan to triple AI chip production next year to meet growing demand. They believe “domestic supply will now be sufficient without Nvidia.” What It Means for the Future With Huawei, Cambricon, Alibaba, and Baidu stepping up, China is positioning itself for long-term technological independence. Nvidia, meanwhile, faces…
Share
BitcoinEthereumNews2025/09/18 01:37
Silver Price Crash Is Over “For Real This Time,” Analyst Predicts a Surge Back Above $90

Silver Price Crash Is Over “For Real This Time,” Analyst Predicts a Surge Back Above $90

Silver has been taking a beating lately, and the Silver price hasn’t exactly been acting like a safe haven. After running up into the highs, the whole move reversed
Share
Captainaltcoin2026/02/07 03:15